Assignee
ONCOMED PHARM INC
US·63 granted patents·50 pending applications·532 citations·filing 2006–2021
Top patents by PatentIndex Score
113 records- 0198US9327014B2Immunotherapy with binding agentsONCOMED PHARM INC·Filed 2013·Granted May 3, 2016·30 cites·15 claims
- 0298US9309311B2Method for making Heteromultimeric moleculesONCOMED PHARM INC·Filed 2013·Granted Apr 12, 2016·40 cites·9 claims
- 0398US7982013B2Frizzled-binding agents and uses thereofONCOMED PHARM INC·Filed 2009·Granted Jul 19, 2011·41 cites·28 claims
- 0498US7723477B2Compositions and methods for inhibiting Wnt-dependent solid tumor cell growthONCOMED PHARM INC·Filed 2006·Granted May 25, 2010·40 cites·40 claims
- 0597US9724390B2Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agentsONCOMED PHARM INC·Filed 2016·Granted Aug 8, 2017·15 cites·17 claims
- 0697US8858941B2VEGF/DLL4 binding agents and uses thereofONCOMED PHARM INC·Filed 2012·Granted Oct 14, 2014·31 cites·25 claims
- 0796US7750124B2Anti-human DLL4 antibodies and compositionsONCOMED PHARM INC·Filed 2007·Granted Jul 6, 2010·46 cites·13 claims
- 0895US10112997B2Tight-binding agents and uses thereofONCOMED PHARM INC·Filed 2016·Granted Oct 30, 2018·24 cites·17 claims
- 0995US7919092B2Antibodies to notch receptorsONCOMED PHARM INC·Filed 2007·Granted Apr 5, 2011·27 cites·21 claims
- 1094US9573998B2Antibodies against human FZD5 and FZD8ONCOMED PHARM INC·Filed 2015·Granted Feb 21, 2017·7 cites·14 claims
- 1194US9023621B2Methods for identifying and isolating cells expressing a polypeptideONCOMED PHARM INC·Filed 2013·Granted May 5, 2015·13 cites·20 claims
- 1293US9574009B2Polynucleotides encoding VEGF/DLL4 binding agentsONCOMED PHARM INC·Filed 2016·Granted Feb 21, 2017·8 cites·17 claims
- 1393US9376488B2VEGF binding antibodiesONCOMED PHARM INC·Filed 2014·Granted Jun 28, 2016·12 cites·16 claims
- 1493US9109025B2Anti-RSPO2 antibodiesONCOMED PHARM INC·Filed 2014·Granted Aug 18, 2015·9 cites·19 claims
- 1593US8883736B2Compositions and methods for treating and diagnosing cancerONCOMED PHARM INC·Filed 2013·Granted Nov 11, 2014·10 cites·19 claims
- 1692US9879084B2Modified immunoglobulin molecules that specifically bind human VEGF and DLL4ONCOMED PHARM INC·Filed 2017·Granted Jan 30, 2018·7 cites·20 claims
- 1792US9228020B2Compositions and methods for diagnosing and treating cancerONCOMED PHARM INC·Filed 2013·Granted Jan 5, 2016·14 cites·32 claims
- 1892US8975044B2Polynucleotides encoding for frizzled-binding agents and uses thereofONCOMED PHARM INC·Filed 2013·Granted Mar 10, 2015·7 cites·20 claims
- 1991US9040044B2Compositions and methods for treating and diagnosing cancerONCOMED PHARM INC·Filed 2013·Granted May 26, 2015·7 cites·28 claims
- 2091US8945878B2Methods for identifying and isolating cells expressing a polypeptideONCOMED PHARM INC·Filed 2013·Granted Feb 3, 2015·7 cites·19 claims
- 2190US9109024B2Anti-RSPO1 antibodies and uses thereofONCOMED PHARM INC·Filed 2014·Granted Aug 18, 2015·5 cites·21 claims
- 2290US8765913B2Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cellsONCOMED PHARM INC·Filed 2012·Granted Jul 1, 2014·9 cites·65 claims
- 2389US10870693B2Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agentONCOMED PHARM INC·Filed 2018·Granted Dec 22, 2020·3 cites·22 claims
- 2489US10232017B2Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptidesONCOMED PHARM INC·Filed 2017·Granted Mar 19, 2019·6 cites·18 claims
- 2589US9599620B2Methods and monitoring of treatment with a DLL4 antagonistONCOMED PHARM INC·Filed 2013·Granted Mar 21, 2017·7 cites·21 claims
- 2689US9273139B2Monoclonal antibodies against frizzledONCOMED PHARM INC·Filed 2013·Granted Mar 1, 2016·5 cites·18 claims
- 2789US8945547B2Notch1 receptor antibodies and methods of treatmentONCOMED PHARM INC·Filed 2013·Granted Feb 3, 2015·6 cites·19 claims
- 2889US8921106B2Antibodies that bind the glutamate ligand binding region of NOTCH3ONCOMED PHARM INC·Filed 2013·Granted Dec 30, 2014·7 cites·15 claims
- 2988US9168300B2MET-binding agents and uses thereofONCOMED PHARM INC·Filed 2014·Granted Oct 27, 2015·6 cites·21 claims
- 3088US9132189B2Notch1 binding agents and methods of use thereofONCOMED PHARM INC·Filed 2013·Granted Sep 15, 2015·5 cites·24 claims
- 3188US8980260B2Monoclonal antibody that binds human notch2 and notch3ONCOMED PHARM INC·Filed 2013·Granted Mar 17, 2015·5 cites·16 claims
- 3287US10730940B2VEGF/DLL4 binding agents and uses thereofONCOMED PHARM INC·Filed 2017·Granted Aug 4, 2020·1 cites·18 claims
- 3387US10544219B2TIGIT-binding agents and uses thereofONCOMED PHARM INC·Filed 2018·Granted Jan 28, 2020·5 cites·22 claims
- 3487US9228013B2Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cellONCOMED PHARM INC·Filed 2014·Granted Jan 5, 2016·3 cites·12 claims
- 3587US8945873B2Polynucleotides encoding Notch receptor antibodiesONCOMED PHARM INC·Filed 2013·Granted Feb 3, 2015·6 cites·28 claims
- 3687US8945874B2Polynucleotides encoding NOTCH1 receptor antibodiesONCOMED PHARM INC·Filed 2013·Granted Feb 3, 2015·5 cites·22 claims
- 3787US8784811B2Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1ONCOMED PHARM INC·Filed 2013·Granted Jul 22, 2014·6 cites·18 claims
- 3886US9511139B2Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agentONCOMED PHARM INC·Filed 2014·Granted Dec 6, 2016·8 cites·25 claims
- 3984US9181333B2RSPO3 binding agents and uses thereofONCOMED PHARM INC·Filed 2013·Granted Nov 10, 2015·5 cites·15 claims
- 4083US9359444B2Methods and monitoring of treatment with a Wnt pathway inhibitorONCOMED PHARM INC·Filed 2014·Granted Jun 7, 2016·6 cites·29 claims
- 4183US9266959B2Methods of treating neuroendocrine tumors using frizzled-binding agentsONCOMED PHARM INC·Filed 2013·Granted Feb 23, 2016·6 cites·20 claims
- 4282US9982042B2Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agentONCOMED PHARM INC·Filed 2016·Granted May 29, 2018·3 cites·51 claims
- 4381US9914771B2Method for making heteromultimeric moleculesONCOMED PHARM INC·Filed 2016·Granted Mar 13, 2018·2 cites·18 claims
- 4480US11046760B2Combination therapy for treatment of diseaseONCOMED PHARM INC·Filed 2018·Granted Jun 29, 2021·2 cites·19 claims
- 4580US9598497B2RSPO3 binding agents and uses thereofONCOMED PHARM INC·Filed 2015·Granted Mar 21, 2017·2 cites·21 claims
- 4679US9480744B2Methods for treating melanomaONCOMED PHARM INC·Filed 2013·Granted Nov 1, 2016·3 cites·20 claims
- 4778US9732139B2Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptorONCOMED PHARM INC·Filed 2015·Granted Aug 15, 2017·1 cites·28 claims
- 4878US9610348B2Compositions and methods for treating and diagnosing cancerONCOMED PHARM INC·Filed 2014·Granted Apr 4, 2017·1 cites·24 claims
- 4978US9579361B2Wnt antagonist and methods of treatment and screeningONCOMED PHARM INC·Filed 2015·Granted Feb 28, 2017·1 cites·35 claims
- 5077US9499613B2Notch1 receptor binding agents and methods of use thereofONCOMED PHARM INC·Filed 2014·Granted Nov 22, 2016·1 cites·23 claims
Showing the top 50 of 113 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →